In summary, we demonstrate here a prolonged production of CXCL10 in cancer patients that respond effectively after receiving BCG instillations, and we propose that this in vivo immune response could provide a new tool to measure the strength of the BCG-stimulated immune response against cancer in patients. This evidence concerns the gene CXCL10 and cancer.